The firm is preparing to test a gene replacement therapy that uses an ultrasound-mediated strategy to deliver a full-length ...
The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.
Innovent Biologics will commercialize Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China, where it is called Verzenios, the companies announced Tuesday. Lilly will retain rights to ...
The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results